Teva commences commercial launch of Escitalopram Oxalate Tablets

Download PDF Copy

Editorial Checklist

Reviewed

TevaMar 15 2012

NewsGuard 100/100 Score

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro® Tablets. The brand product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data.

As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

Source:

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anxiety, Anxiety Disorder, Biotechnology, Depression, Generic Drug, Lexapro, Medicaid, Medicare, Mental Health, New Drug Application, Oncology, Pain, Pharmaceuticals, Protonix

Comments (0)

Download PDF Copy

Suggested Reading

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

New target identified for potential ALS therapy

New target identified for potential ALS therapy

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes